MedTrace Logo

Effectiveness of Deep Dry Needling on Muscle Tone in Healthy Subjects

NCT02575586 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-10-20

No results posted yet for this study

Summary

The main objective of this study is to analyze the effect of dry needling of the soleus muscle to modulate muscle tone in healthy non-injured subjects. The secondary objective is to study if effects occur due to changes in the neural or mechanical component (or both).

Hypothesis: Deep Dry Needling of the latent medial Myofascial Trigger Point (MTrP) of the soleus muscle produces changes in muscle tone varying the passive resistance torque at a rate of 180º/ s.

Conditions

  • Muscle Tone Abnormalities

Interventions

DEVICE

Intervention-Dry Needling

Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle. 1 session in soleus muscle moving the needle up and down ten times.

DEVICE

Control-Dry Needling

Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band. 1 session in soleus muscle moving the needle up and down ten times.

Sponsors & Collaborators

  • Hospital Nacional de Parapléjicos de Toledo

    collaborator OTHER

  • Universidad San Jorge

    collaborator OTHER

  • University of Castilla-La Mancha

    lead OTHER

Principal Investigators

  • Julio Gomez Soriano, PhD · University of Castilla-La Mancha

  • Carolina Jiménez Sánchez, MSc · Universidad San Jorge

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2017-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02575586 on ClinicalTrials.gov